(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/080832 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 47/48* (2006.01)
C07K 16/30 (2006.01) *A61K 39/395* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/EP2008/068270

(22) International Filing Date:
23 December 2008 (23.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/016,614	26 December 2007 (26.12.2007)	US
61/087,590	8 August 2008 (08.08.2008)	US
61/087,466	8 August 2008 (08.08.2008)	US

(71) Applicants *(for all designated States except US)*: **BIOTEST AG** [DE/DE]; Landsteinerstrasse 5, D-63303 Dreieich (DE). **IMMUNOGEN, INC** [US/US]; 830 Winter Street, Waltham, Massachusetts 02451-1477 (US). **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 44 Binney Street, Boston, Massachusetts 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DAELKEN, Benjamin** [DE/DE]; Eleonore-Sterling-Strasse 40, 60433 Frankfurt Am Main (DE). **UHEREK, Christoph** [DE/DE]; Lachenwoerthsweg 6, 63500 Seligenstadt (DE). **ANDERSON, Kenneth** [US/US]; 264 Weston Road, Wellesley, Massachusetts 02482 (US). **HIDESHIMA, Teru** [JP/US]; 72 Francis Street, Brookline, Massachusetts 02446 (US). **BRUECHER, Christoph** [DE/DE]; Unter den Tannen 3a, 65760 Eschborn (DE).

(74) Agent: **DANIELS, Jeffrey, Nicholas**; Bedford House, John Street, London Greater London WC1N 2BF (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING TUMOR CELLS

(57) **Abstract:** Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This deminished adhesion renders the tumor cells not only susceptible to the immunconjugate, but also to other agents, in particular cytotoxic agents.

WO 2009/080832 A1